Parkinson’s Disease – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Wed, 18 Oct 2023 23:54:48 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Parkinson’s Disease – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review https://www.cannabisclinicians.org/2023/10/18/emerging-therapeutic-potential-of-cannabidiol-cbd-in-neurological-disorders-a-comprehensive-review/ Wed, 18 Oct 2023 23:54:48 +0000 https://www.cannabisclinicians.org/?p=29460 Δ9-Tetrahydrocannabinol (Δ9-THC) is a principal psychoactive extract of Cannabis sativa and has been traditionally used as palliative medicine for neuropathic pain. Cannabidiol (CBD), an extract of hemp species, has recently attracted increased attention as a cancer treatment, but Δ9-THC is also requiring explored pharmacological application. This study evaluated the pharmacological effects of Δ9-THC in two human colorectal cancer cell lines. We inves-tigated whether Δ9-THC treatment induces cell death in human colorectal cancer cells.

The post Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review appeared first on Society of Cannabis Clinicians.

]]> Cannabinoids in Treating Parkinson’s Disease Symptoms: A Systematic Review of Clinical Studies https://www.cannabisclinicians.org/2023/06/03/cannabinoids-in-treating-parkinsons-disease-symptoms-a-systematic-review-of-clinical-studies/ Sat, 03 Jun 2023 19:24:00 +0000 https://www.cannabisclinicians.org/?p=28745 Parkinson’s disease (PD) is a serious neurodegenerative condition impacting many individuals worldwide. There is a need for new non-invasive treatments of PD. Cannabinoids in the form of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may offer utility as treatment, and our objective was hence to conduct a systematic review regarding the clinical evidence for the efficacy and safety of cannabinoids in treating PD.

The post Cannabinoids in Treating Parkinson’s Disease Symptoms: A Systematic Review of Clinical Studies appeared first on Society of Cannabis Clinicians.

]]> Long-term safety of medical cannabis in Parkinson’s disease: A retrospective case-control study https://www.cannabisclinicians.org/2023/05/27/long-term-safety-of-medical-cannabis-in-parkinsons-disease-a-retrospective-case-control-study/ Sun, 28 May 2023 00:35:55 +0000 https://www.cannabisclinicians.org/?p=28695 Whole-plant medical cannabis (MC) products are widely used for controlling symptoms associated with Parkinson's disease (PD). Despite its widespread use, few studies have investigated the long-term impact of MC on the progression of PD or its safety profile. This study examined the effects of MC on PD in a real-life setting. A retrospective case-control study of 152 idiopathic PD patients (mean age 69.1 ± 9.0 years), followed at the Sheba Medical Center Movement Disorders Institute (SMDI) from 2008 to 2022 was conducted. Seventy-six patients who used licensed whole-plant medical cannabis (MC) for at least a year were compared to a matched group who did not receive MC in terms of their Levodopa Equivalent Daily Dose (LEDD), Hoehn and Yahr (H&Y) stage, and cognitive, depressive, and psychotic symptoms.

The post Long-term safety of medical cannabis in Parkinson’s disease: A retrospective case-control study appeared first on Society of Cannabis Clinicians.

]]> Medical Cannabis in the Treatment of Parkinson’s Disease https://www.cannabisclinicians.org/2023/04/22/medical-cannabis-in-the-treatment-of-parkinsons-disease/ Sat, 22 Apr 2023 18:24:24 +0000 https://www.cannabisclinicians.org/?p=28427 Medical cannabis (MC) has recently garnered interest as a potential treatment for neurologic diseases, including Parkinson’s disease (PD). A retrospective chart review was conducted to explore the impact of MC on the symptomatic treatment of patients with PD. Patients with PD treated with MC in the normal course of clinical practice were included (n = 69). Data collected from patient charts included MC ratio/formulation changes, PD symptom changes after initiation of MC, and adverse events (AEs) from MC use. Information regarding changes in concomitant medications after MC initiation, including opioids, benzodiazepines, muscle relaxants, and PD medications, was also collected.

The post Medical Cannabis in the Treatment of Parkinson’s Disease appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol goes nuclear: The role of PPARγ https://www.cannabisclinicians.org/2023/03/17/cannabidiol-goes-nuclear-the-role-of-ppar%ce%b3/ Fri, 17 Mar 2023 22:41:53 +0000 https://www.cannabisclinicians.org/?p=28080 Cannabidiol (CBD) is one of the main phytocannabinoids found in Cannabis sativa. In contrast to Δ9-tetrahydrocannabinol, it has a low affinity for cannabinoid receptors CB1 and CB2, thereby it does not induce significant psychoactive effects. However, CBD may interact with other receptors, including peroxisome proliferator-activated receptor gamma (PPARγ). CBD is a PPARγ agonist and changes its expression. There is considerable evidence that CBD's effects are mediated by its interaction with PPARγ. So, we reviewed studies related to the interaction of CBD and PPARγ.

The post Cannabidiol goes nuclear: The role of PPARγ appeared first on Society of Cannabis Clinicians.

]]> Cannabis sativa and Cannabidiol: A Therapeutic Strategy for the Treatment of Neurodegenerative Diseases? https://www.cannabisclinicians.org/2022/11/19/cannabis-sativa-and-cannabidiol-a-therapeutic-strategy-for-the-treatment-of-neurodegenerative-diseases/ Sat, 19 Nov 2022 22:48:21 +0000 https://www.cannabisclinicians.org/?p=27177 This work is a literature review, presenting the current state of the use of cannabinoids on neurodegenerative diseases. The emphasis is on Parkinson’s (PD) and Alzheimer’s (AD) diseases, the two most prevalent neurological diseases. The review goes from Cannabis sativa and its hundreds of bioactive compounds to Δ9-tetrahydrocannabinol (THC) and mainly cannabidiol (CBD) and their interactions with the endocannabinoid receptors (CB1 and CB2).

The post Cannabis sativa and Cannabidiol: A Therapeutic Strategy for the Treatment of Neurodegenerative Diseases? appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol for neurodegenerative disorders: A comprehensive review https://www.cannabisclinicians.org/2022/11/19/cannabidiol-for-neurdegenerative-disorders-a-comprehensive-review/ Sat, 19 Nov 2022 22:21:30 +0000 https://www.cannabisclinicians.org/?p=27166 This review briefly discusses the role of inflammation and oxidative stress in neurodegeneration and demonstrates the neuroprotective effect of cannabidiol, highlighting its general mechanism of action and disease-specific pathways in Parkinson’s disease (PD) and Alzheimer’s disease (AD). Furthermore, we have summarized the preclinical and clinical findings on the therapeutic promise of CBD in PD and AD, shed light on the importance of determining its therapeutic window, and provide insights into identifying promising new research directions.

The post Cannabidiol for neurodegenerative disorders: A comprehensive review appeared first on Society of Cannabis Clinicians.

]]> Higher Risk, Higher Reward? Self-Reported Effects of Real-World Cannabis Use in Parkinson’s Disease https://www.cannabisclinicians.org/2022/02/02/higher-risk-higher-reward-self-reported-effects-of-real-world-cannabis-use-in-parkinsons-disease/ Wed, 02 Feb 2022 17:42:03 +0000 https://www.cannabisclinicians.org/?p=26102 IDespite limited evidence, people with Parkinson’s disease (PD) use cannabis for therapeutic purposes. Given barriers to performing randomized trials, exploring real-world experiences with cannabis in PD is valuable. Investigate the frequency and magnitude of symptomatic effects reported with cannabis use in PD. An anonymous, 15-question, web-based survey was deployed on Fox Insight. Cannabis product types were defined (by relative tetrahydrocannabinol [THC] and cannabidiol [CBD] content) and respondents were asked to reference product labels. Questions focused on use patterns and subjective effects on 36 predefined symptoms (rated −2-markedly worse to +2-markedly better).

The post Higher Risk, Higher Reward? Self-Reported Effects of Real-World Cannabis Use in Parkinson’s Disease appeared first on Society of Cannabis Clinicians.

]]> Cannabinoids and the expanded endocannabinoid system in neurological disorders. https://www.cannabisclinicians.org/2020/01/01/cannabinoids-and-the-expanded-endocannabinoid-system-in-neurological-disorders/ Wed, 01 Jan 2020 13:30:10 +0000 https://www.cannabisclinicians.org/?p=17303 Authors: Luigia Cristino, Tiziana Bisogno, Vincenzo Di Marzo
Nature Reviews Neurology, January 2020
---
Anecdotal evidence that cannabis preparations have medical benefits together with the discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated efforts to develop cannabinoid-based therapeutics. These efforts have been marked by disappointment, es...

The post Cannabinoids and the expanded endocannabinoid system in neurological disorders. appeared first on Society of Cannabis Clinicians.

]]> Cannabis in Parkinson’s Disease: Hype or help? https://www.cannabisclinicians.org/2018/02/01/cannabis-in-parkinsons-disease-hype-or-help/ Thu, 01 Feb 2018 19:36:06 +0000 https://www.cannabisclinicians.org/?p=15606 Authors: Tina Mainka, Jan Stork, Ute Hidding, Carsten Buhmann
Fortschritte der Neurologie · Psychiatrie, February 2018
---
Cannabis buds and extracts as well as synthetic cannabinoids have been available on prescription to patients with severe diseases since March 2017, with the costs covered by health insurance companies.The prescription of medical marihuana is not restricted to specific symptoms...

The post Cannabis in Parkinson’s Disease: Hype or help? appeared first on Society of Cannabis Clinicians.

]]>